Qiu J D, Zhu R Z, Chen H, Zhang T P
Department of General Surgery,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China.
School of Medicine,Tsinghua University,Beijing 100089,China.
Zhonghua Wai Ke Za Zhi. 2021 Mar 1;59(3):232-236. doi: 10.3760/cma.j.cn112139-20200708-00549.
Pancreatic cancer is a highly malignant tumor in the digestive system.The role of neoadjuvant therapy in pancreatic cancer has been highlighted with the understanding of pancreatic cancer biological behavior and popularization of comprehensive treatment.Therefore,Study group of Pancreatic Surgery in China Society of Surgery of Chinese Medical Association and Pancreatic Disease Committee of China Research Hospital Association has formulated the guidelines for neoadjuvant therapy of pancreatic cancer in China(2020 edition).This guidelines elaborated key issues of the neoadjuvant therapy of pancreatic cancer,and provided reference for clinical practice.This article aims to interpret the guidelines about the preparation before neoadjuvant therapy, indication, regimen selection, therapeutic effect evaluation and surgery strategy, with further discussion about controversial issues of neoadjuvant therapy in pancreatic cancer.
胰腺癌是消化系统中一种高度恶性的肿瘤。随着对胰腺癌生物学行为的认识以及综合治疗的普及,新辅助治疗在胰腺癌中的作用日益凸显。因此,中华医学会外科学分会胰腺外科学组和中国研究型医院学会胰腺疾病专业委员会制定了《中国胰腺癌新辅助治疗指南(2020版)》。本指南阐述了胰腺癌新辅助治疗的关键问题,为临床实践提供了参考。本文旨在解读关于新辅助治疗前准备、适应证、方案选择、疗效评估及手术策略等方面的指南内容,并进一步探讨胰腺癌新辅助治疗中的争议问题。